spacer
home > epc > winter 2009 > bridging the data gap
PUBLICATIONS
European Pharmaceutical Contractor

Bridging the Data Gap

 

Computable semantic interoperability (CSI) is the means to share information between disparate information systems in such a way that the information retains its significance (semantics), so that it can be used in meaningful ways. Often, information that is collected in one system is only really useful within that system; to communicate or share that information to another system in a meaningful way for machine processing (as opposed to human readability – that is to say document transfer) involves complex and expensive interfacing, with many mappings and transformation processes.

CSI:THE BENEFITS TO PHARMACOVIGILANCE

The science of pharmacovigilance involves collecting and analysing adverse event information collected from a range of sources – spontaneous reports from the global healthcare domain as well as more focused study reporting. Although individual reports can have value within themselves, the real benefit of this information lies in detecting trends or ‘signals’, and to do this effectively, all available data must be gathered together into standard structures for investigation, while clearly retaining its original meaning. It may also be useful to compare the adverse event information with other broader healthcare information to understand background event rates. This is reflected in the value chain of ‘data to information to knowledge to wisdom’.

Individual data elements need to be gathered together, while retaining their context and meaning, to produce information. This information can be analysed, processed and interpreted in a variety of ways, again still retaining its context and meaning, so as not to produce incorrect results, and this analysis and interpretation produces knowledge. This evidence-based knowledge, gained directly from the data and information, can then be blended with other sources that are applicable in the particular situation, to suggest an appropriate course of action in the situation.

This is easily illustrated in a clinical trials scenario: enormous amounts of data are gathered from the trial participants, including the adverse event data, and this needs to be meaningfully brought together to produce the information needed for the analyses that occur periodically through the trial period and in preparation for license submission. These analyses and interpretation provide ever increasing information about the safety of the investigational product, which should then be blended together with all the other available knowledge to enable wise decisions to be taken on further development, license application wording, specific population groups for further trialling or use, and so on.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Julie James qualified as a pharmacist in the UK before moving into medical informatics, where she has worked for the last 15 years. In 2002, Julie became a partner in an independent health informatics consultancy, Blue Wave Informatics, which  specialises in ‘all things medicines’ – their descriptive terminology, their use in clinical applications, and in communication, such as adverse event and other safety reporting. Julie is a co-chair of the Pharmacy Special Interest Group of IHTDO, vocabulary facilitator for the Pharmacy Work Group in HL7, and an active member of the HL7 Patient Safety Work Group.

Email: julie_james@bluewaveinformatics.co.uk

spacer
Julie James
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator, with the UK and France close behind

Paris, 19th August 2019: As predicted by the ‘European drug delivery and packaging’ report earlier this year, new data shows innovation in drug delivery is accelerating across Europe – with provisional findings from the Pharmapack Innovation Index (2020) showing that Switzerland has over taken Germany as Europe’s most innovative drug delivery market.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement